## Peter M Haddad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8800656/publications.pdf

Version: 2024-02-01

143 papers 6,610 citations

108046 37 h-index 78623 77 g-index

155 all docs

155 docs citations

155 times ranked 6696 citing authors

#	Article	IF	CITATIONS
1	Abnormal corneal nerve morphology and brain volume in patients with schizophrenia. Scientific Reports, 2022, 12, 1870.	1.6	5
2	Characteristics of $100$ consecutive patients with COVID-19 referred to consultation-liaison psychiatry services in Qatar: A comparison of patients with delirium versus other psychiatric diagnoses. Qatar Medical Journal, $2022$ , $2022$ , .	0.2	1
3	Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar. BMC Psychiatry, 2021, 21, 149.	1.1	5
4	Ischaemic stroke as the presenting feature of COVID-19: a series of three cases from Qatar. Oxford Medical Case Reports, 2021, 2021, omab006.	0.2	3
5	Suspected Agomelatine-induced restless legs syndrome: a case report. BMC Psychiatry, 2021, 21, 180.	1.1	2
6	Prevalence and Potential Determinants of COVID-19 Vaccine Hesitancy and Resistance in Qatar: Results from a Nationally Representative Survey of Qatari Nationals and Migrants between December 2020 and January 2021. Vaccines, 2021, 9, 471.	2.1	45
7	Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry,the, 2021, 8, 471-486.	3.7	36
8	Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1917-1926.	1.0	6
9	Psychiatric presentations of patients with COVID-19: a retrospective review of 100 consecutive patients seen by liaison psychiatry services. BJPsych Open, 2021, 7, S257-S258.	0.3	O
10	Mental health stigma: the role of dualism, uncertainty, causation and treatability. Annals of General Psychiatry, 2021, 34, e100498.	1.1	9
11	Support and attitudes of Qatar mental health professionals to a proposed mental health inpatient smoking ban: Results of a crossâ€sectional survey. Journal of Psychiatric and Mental Health Nursing, 2021, , .	1.2	6
12	The COVID-19 pandemic: an opportunity to make mental health a higher public health priority. BJPsych Open, 2021, 7, e172.	0.3	8
13	Withdrawal-associated relapse is a potential source of bias – Authors' reply. Lancet Psychiatry,the, 2021, 8, 748-749.	3.7	O
14	Delirious mania in a patient with COVID-19 pneumonia. BMJ Case Reports, 2021, 14, e243816.	0.2	7
15	Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia. JAMA Psychiatry, 2021, , .	6.0	4
16	Psychiatric inpatients' views of their mental health, and their experience of social change, during the pandemic: A report from Qatar. Journal of Psychiatric and Mental Health Nursing, 2021, , .	1.2	1
17	Buspirone in the management of refractory irritable bowel syndrome. Medicine (United States), 2021, 100, e28003.	0.4	1
18	Factors associated with depression and anxiety in the adult population of Qatar after the first COVID-19 wave: a cross-sectional study. Discover Psychology, 2021, 1, 1.	0.4	O

#	Article	IF	Citations
19	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2020, 34, 3-78.	2.0	259
20	Psychiatric presentation of patients with acute SARS-CoV-2 infection: a retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team. BJPsych Open, 2020, 6, e109.	0.3	44
21	Ten principles of good psychiatric prescribing. Medicine, 2020, 48, 796-799.	0.2	0
22	Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. BMC Psychiatry, 2020, 20, 199.	1.1	11
23	A Brief History of Psychopharmacology. , 2020, , 1-34.		0
24	Psychiatric Drug Discovery and Development. , 2020, , 35-68.		2
25	Neurotransmission and Mechanisms of Drug Action. , 2020, , 69-123.		0
26	Pharmacodynamics and Pharmacokinetics., 2020, , 124-150.		0
27	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
28	Good Clinical Practice in Psychopharmacology. , 2020, , 203-203.		0
29	Drugs to Treat Depression. , 2020, , 227-267.		0
30	Drugs to Treat Anxiety and Insomnia. , 2020, , 268-289.		0
31	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq1 1	0.784314	ł rgBT /Overl
32	Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine. , 2020, , 362-391.		0
33	Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD). , 2020, , 392-432.		1
34	Drugs to Treat Dementia. , 2020, , 433-453.		0
35	Drugs to Treat Substance Use Disorders. , 2020, , 454-494.		0
36	Electroconvulsive Therapy and Neuromodulation Therapies. , 2020, , 495-495.		0

#	Article	IF	Citations
37	Psychotropic Drug Treatment in Childhood and Adolescence. , 2020, , 525-542.		0
38	Psychotropic Drug Treatment in Later Life. , 2020, , 543-576.		0
39	Psychotropic Prescribing in Pregnancy and Lactation. , 2020, , 577-598.		O
40	The Clinical Management of Acute Disturbance Including Rapid Tranquillisation., 2020,, 599-618.		0
41	Antipsychotics, Weight Gain and Metabolic Risk. , 2020, , 619-619.		0
42	Brief psychotic disorder associated with quarantine and mild COVID-19. BMJ Case Reports, 2020, 13, e240088.	0.2	25
43	Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14–18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). Trials, 2019, 20, 395.	0.7	11
44	Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey. Schizophrenia Research, 2019, 211, 105-107.	1.1	1
45	Marketing medicines: charting the rise of modern therapeutics through a systematic review of adverts in UK medical journals (1950–1980). British Journal of Clinical Pharmacology, 2018, 84, 1668-1685.	1.1	7
46	Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. Lancet Psychiatry,the, 2018, 5, 411-423.	3.7	50
47	Examining the †psychopharmacology revolution†(1950†1980) through the advertising of psychoactive drugs in the <i>British Medical Journal </i> i>. Journal of Psychopharmacology, 2018, 32, 1056-1066.	2.0	5
48	The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Therapeutic Advances in Psychopharmacology, 2018, 8, 303-318.	1.2	129
49	Medication nonadherence in bipolar disorder: a narrative review. Therapeutic Advances in Psychopharmacology, 2018, 8, 349-363.	1.2	105
50	Stand-alone cognitive behavioural therapy is not in clinical equipoise with antipsychotic treatment – Author's reply. Lancet Psychiatry,the, 2018, 5, 540-541.	3.7	0
51	Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Therapeutic Advances in Psychopharmacology, 2018, 8, 185-197.	1.2	11
52	Rethinking the spectrum of mood disorders: implications for diagnosis and management – Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September 2017, Paris, France. Therapeutic Advances in Psychopharmacology, 2018, 8, 1-16.	1.2	6
53	Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1-8.	1.0	23
54	Pilot study of a culturally adapted psychoeducation (CaPE) intervention for bipolar disorder in Pakistan. International Journal of Bipolar Disorders, 2017, 5, 3.	0.8	17

#	Article	IF	Citations
55	Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study. Annals of General Psychiatry, 2017, 16, 12.	1.2	71
56	A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial. Psychosis, 2017, 9, 193-204.	0.4	6
57	The relationship between childhood trauma and adult psychosis in a UK Early Intervention Service: results of a retrospective case note study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 269-273.	1.0	8
58	Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technology Assessment, 2017, 21, 1-56.	1.3	28
59	Dr Correll and Colleagues Reply. Journal of Clinical Psychiatry, 2017, 78, e1062.	1.1	1
60	Ten principles of good psychiatric prescribing. Medicine, 2016, 44, 745-747.	0.2	0
61	Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability. Therapeutic Advances in Psychopharmacology, 2016, 6, 162-171.	1.2	3
62	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry,the, 2016, 3, 117-127.	3.7	30
63	The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2016, 77, 1-24.	1.1	267
64	Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use. Therapeutic Advances in Psychopharmacology, 2015, 5, 214-223.	1.2	9
65	Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. Therapeutic Advances in Psychopharmacology, 2015, 5, 339-350.	1.2	14
66	Diet, exercise and the metabolic syndrome in schizophrenia: A cross-sectional study. Schizophrenia Research, 2015, 169, 494-495.	1.1	14
67	Guidance on switching away from Piportil Depot $\hat{A}^{\otimes}$ (pipotiazine palmitate) injection. British Journal of Psychiatry, 2015, 206, 521-521.	1.7	3
68	A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial. Trials, 2015, 16, 9.	0.7	14
69	Ambiguous findings concerning potential advantages of depot antipsychotics. Current Opinion in Psychiatry, 2015, 28, 216-221.	3.1	47
70	Glasgow Antipsychotic Side-effects Scale for Clozapine $\hat{a}\in$ " Development and validation of a clozapine-specific side-effects scale. Schizophrenia Research, 2015, 168, 505-513.	1.1	46
71	Managing inadequate antidepressant response in depressive illness. British Medical Bulletin, 2015, 115, 183-201.	2.7	17
72	Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study). Efficacy and Mechanism Evaluation, 2015, 2, 1-98.	0.9	5

#	Article	IF	Citations
73	Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures, 2014, 5, 43.	0.7	396
74	Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics. Neuropsychiatric Disease and Treatment, 2014, 10, 1953.	1.0	1
75	A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Therapeutic Advances in Psychopharmacology, 2014, 4, 179-185.	1.2	41
76	SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology, 2014, 4, 15-21.	1.2	36
77	Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans. European Neuropsychopharmacology, 2014, 24, 822-835.	0.3	105
78	Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). BMC Psychiatry, 2013, 13, 205.	1.1	7
79	Improving Treatment Adherence in Your Patients with Schizophrenia. Clinical Drug Investigation, 2013, 33, 97-107.	1.1	38
80	Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia. Evidence-Based Mental Health, 2013, 16, 109-109.	2.2	8
81	The size, burden and cost of disorders of the brain in the UK. Journal of Psychopharmacology, 2013, 27, 761-770.	2.0	163
82	Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa. Patient Preference and Adherence, 2013, 7, 121.	0.8	25
83	Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. Journal of Psychopharmacology, 2013, 27, 358-365.	2.0	35
84	Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head–head comparisons. Journal of Psychopharmacology, 2012, 26, 15-26.	2.0	60
85	Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications. International Clinical Psychopharmacology, 2012, 27, 275-282.	0.9	14
86	Challenges in the management of early psychosis. Journal of Psychopharmacology, 2012, 26, 6-7.	2.0	0
87	Bipolar disorder. BMJ, The, 2012, 345, e8508-e8508.	3.0	173
88	Ten principles of good psychiatric prescribing. Medicine, 2012, 40, 674-675.	0.2	0
89	Weight Change From 3-Year Observational Data. Journal of Clinical Psychiatry, 2012, 73, e749-e755.	1.1	47
90	A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia. American Journal of Psychiatry, 2011, 168, 603-609.	4.0	552

#	Article	IF	Citations
91	The place of observational studies in assessing the effectiveness of depot antipsychotics. Schizophrenia Research, 2011, 131, 260-261.	1.1	21
92	Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. Journal of Psychopharmacology, 2011, 25, 306-313.	2.0	36
93	Prescribing antidepressants for depression: time to be dimensional and inclusive. British Journal of General Practice, 2011, 61, 50-52.	0.7	6
94	Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 531-540.	0.7	68
95	Antidepressant drugs. Side Effects of Drugs Annual, 2010, , 29-40.	0.6	0
96	Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research, 2010, 176, 109-113.	1.7	359
97	First-generation antipsychotic long-acting injections <i>v</i> . oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry, 2009, 195, s20-s28.	1.7	89
98	CANMAT Guidelines for depression: Clear and user-friendly. Journal of Affective Disorders, 2009, 117, S3-S4.	2.0	10
99	Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry, 2009, 9, 46.	1.1	23
100	A review of valproate in psychiatric practice. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 539-551.	1.5	119
101	Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology, 2008, 23, S15-S26.	0.7	175
102	Improving drug safety and tolerability in psychiatric clinical practice. Human Psychopharmacology, 2008, 23, S1-S2.	0.7	1
103	The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. Journal of Psychopharmacology, 2008, 22, 330-332.	2.0	93
104	Aripiprazole in the treatment of primary delusional parasitosis. British Journal of Psychiatry, 2008, 193, 258-258.	1.7	10
105	Adverse effects of antipsychotics as outcome measures. British Journal of Psychiatry, 2007, 191, s64-s70.	1.7	49
106	Recognising and managing antidepressant discontinuation symptoms. Advances in Psychiatric Treatment, 2007, 13, 447-457.	0.6	84
107	Adverse Effects of Atypical Antipsychotics. CNS Drugs, 2007, 21, 911-936.	2.7	364
108	Documentation of extrapyramidal symptoms. Psychiatric Bulletin, 2007, 31, 76-77.	0.3	6

#	Article	IF	CITATIONS
109	Selecting antipsychotics in schizophrenia: lessons from CATIE. Journal of Psychopharmacology, 2006, 20, 332-334.	2.0	15
110	What works in schizophrenia: Depot preparations may improve outcomes. BMJ: British Medical Journal, 2006, 333, 353.1.	2.4	3
111	Prevalence of and Markers for Affective Disorders Among Cancer Patients' Caregivers. Journal of Psychosocial Oncology, 2005, 22, 45-68.	0.6	6
112	Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of Affective Disorders, 2005, 89, 207-212.	2.0	72
113	Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Human Psychopharmacology, 2005, 20, 447-448.	0.7	29
114	Do antidepressants cause dependence?. Epidemiologia E Psichiatria Sociale, 2005, 14, 58-62.	1.0	16
115	The role of lifestyle interventions and weight management in schizophrenia. Journal of Psychopharmacology, 2005, 19, 28-35.	2.0	69
116	Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?. Journal of Psychopharmacology, 2005, 19, 432-433.	2.0	23
117	Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal of Psychopharmacology, 2005, 19, 16-27.	2.0	112
118	Re: Depression, Stroke Diagnosis, and SSRI Discontinuation Syndrome. Canadian Journal of Psychiatry, 2004, 49, 343-344.	0.9	0
119	Changes in Pharmacological treatment for Bipolar Disorder Over Time in Manchester: A Comparison with Lloyd et al. (2003). Journal of Psychopharmacology, 2004, 18, 441-444.	2.0	8
120	Antipsychotics and diabetes: Review of non-prospective data. British Journal of Psychiatry, 2004, 184, s80-s86.	1.7	61
121	Antipsychotic-Induced Hyperprolactinaemia. Drugs, 2004, 64, 2291-2314.	4.9	521
122	Antidepressant discontinuation syndromes. , 2004, , 183-206.		98
123	Clinical trials of antidepressant medications are producing meaningless results. British Journal of Psychiatry, 2003, 183, 102-104.	1.7	43
124	Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death. Drugs, 2002, 62, 1649-1671.	4.9	379
125	Pharmacological management of bipolar depression. Acta Psychiatrica Scandinavica, 2002, 105, 401-403.	2.2	3
126	Antidepressant Discontinuation Syndromes. Drug Safety, 2001, 24, 183-197.	1.4	168

#	Article	IF	CITATIONS
127	Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. Journal of Psychopharmacology, 2001, 15, 293-295.	2.0	22
128	Antidepressant discontinuation (withdrawal) symptoms presenting as  stroke'. Journal of Psychopharmacology, 2001, 15, 139-141.	2.0	21
129	Compulsive heroin use: comorbidity, syndrome or selfâ€medication of lupus erythematosus?. Acta Psychiatrica Scandinavica, 2001, 103, 78-79.	2.2	0
130	Differing Tolerability Profiles Among Atypical Antipsychotics. American Journal of Psychiatry, 2001, 158, 501-501.	4.0	4
131	Misdiagnosis of antidepressant discontinuation symptoms. Acta Psychiatrica Scandinavica, 2000, 102, 466-468.	2.2	14
132	Discontinuation symptoms and psychotropic drugs. Lancet, The, 2000, 355, 1184.	6.3	11
133	Health professionals' views of services for schizophrenia – fragmentation and inequality. Psychiatric Bulletin, 2000, 24, 47-50.	0.3	3
134	Antidepressants aren't addictive: clinicians have depended on them for years. Journal of Psychopharmacology, 1999, 13, 291-292.	2.0	7
135	Do antidepressants have any potential to cause addiction?. Journal of Psychopharmacology, 1999, 13, 300-307.	2.0	67
136	Adjunctive use of olanzapine in the treatment of mania. International Journal of Psychiatry in Clinical Practice, 1999, 3, 213-215.	1.2	1
137	Pharmacists Lack Knowledge of Antidepressant Discontinuation Symptoms. Journal of Clinical Psychiatry, 1999, 60, 125-126.	1.1	1
138	The SSRI discontinuation syndrome. Journal of Psychopharmacology, 1998, 12, 305-313.	2.0	112
139	Nothing but happiness?. Psychiatric Bulletin, 1995, 19, 694-695.	0.3	0
140	Sexual problems associated with dementia: Part 1. Problems and their consequences. International Journal of Geriatric Psychiatry, 1993, 8, 547-551.	1.3	30
141	Sexual problems associated with dementia: Part 2. Aetiology, assessment and treatment. International Journal of Geriatric Psychiatry, 1993, 8, 631-637.	1.3	26
142	First European symposium on ECT: ?Critical history?future trends?. International Journal of Geriatric Psychiatry, 1992, 7, 612-613.	1.3	0
143	Cardiac side effects of psychotropic medication: focus on QTc prolongation and TdP., 0,, 515-531.		0